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Brain metastases (BM) are a common and lethal complication of non-small cell lung cancer
(NSCLC), which portend a poor prognosis. In addition, their management implies sev-
eral challenges including preservation of neurological and neurocognitive function during
surgery or radiation-therapy, minimizing iatrogenic complications of supportive medica-
tions, and optimizing drug delivery across the blood–brain barrier. Despite these challenges,
advancements in combined modality approaches can deliver hope of improved overall sur-
vival and quality of life for a subset of NSCLC patients with BM. Moreover, new drugs
harnessing our greater understanding of tumor biology promise to build on this hope. In
this mini-review, we revised the management of BM in NSCLC including advancements in
neurosurgery, radiation therapy, as well as systemic and supportive therapy.
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INTRODUCTION
Lung cancer is the leading cause of cancer mortality world-
wide, accounting for 1.38 million annual deaths, representing
18.2% of total deaths from cancer (1). Among those, approx-
imately 7.4% of non-small cell lung cancer (NSCLC) patients
will have brain metastases (BM) at presentation (2), and 25–30%
will develop BM during the course of their disease (3). Life-
expectancy for these patients is poor, with a median survival of
only 3.4 months (4). Moreover, many will suffer considerable loss
of autonomy due to neurocognitive and functional deficits, as well
as morbidity associated with medications such as steroids and
anti-epileptic drugs.
Despite these grim realities, there is room for optimism among
identifiable subsets of these patients. A recent published series of
NSCLC patients with synchronous BM receiving surgery or radio-
surgery to the brain and aggressive management of their extracra-
nial disease reported a median overall survival (OS) of 12.1 months
(5). Improved surgical techniques and radiation therapy (RT)
technology, as well as more effective systemic treatments and
multimodality approaches have led to these superior outcomes.
Moreover, renewed hope has emerged from the use of small-
molecule drugs targeting oncogenic mutations, which have shown
promising activity both extra-cranially and intra-cranially (6).
PROGNOSTIC FACTORS
Several variables have been established of prognostic importance
in determining potential outcomes for patients harboring BM.
In 1997, the Radiation Therapy Oncology Group (RTOG) per-
formed a recursive partitioning analysis (RPA) from a historical
database of 1200 patients treated with whole-brain radiation ther-
apy (WBRT) from three RTOG BM trials and published a prog-
nostic scoring system (7). Three scoring classes were identified
based on patients’ Karnofsky performance score (KPS), age, status
of primary tumor, and extent of extracranial disease (Table 1).
Median survival ranged from 2.3 months for patients in class III
to 7.1 months for those in class I.
Since then, several other scoring classifications have been
described (4, 8–11) as shown in Table 1. All these classifica-
tions have limitations, but are able to consistently prognosticate
outcomes based on the defined scoring. Irrespective of the scor-
ing classification used, age, performance status, number of brain
lesions, and the presence of extracranial metastases are the vari-
ables that better define prognosis. Given the high heterogeneity
of the BM patient population, one should not rely exclusively on
these indices when assessing the management for such patients.
A comparative review of five of these prognostic indexes using an
artificial neural network in patients with BM and receiving WBRT
(12) suggests that the graded prognostic assessment index (10) was
the most powerful in predicting survival.
Increasingly, molecular biomarkers are also being identified
with prognostic significance in NSCLC, some with positive [e.g.,
EGFR (del-19 and L858R)] and others with negative (e.g., ERCC1,
BRCA1, TP53, and KRAS) prognostic value (13). In addition,
microarray-derived gene signatures provide the potential for even
greater prognostic ability (14). However, many of these biomark-
ers require further validation, and are not yet ready for entry into
routine clinical practice.
TREATMENT
SUPPORTIVE
Early integration of palliative care in the management of metasta-
tic NSLCC has been demonstrated to improve both quality of life
and mood, and is associated with improved survival despite less
aggressive end of life treatment (15). In addition to general pallia-
tive measures, patients with BM often necessitate additional sup-
portive medications such as steroids and anti-seizure medications.
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Table 1 | Prognostic indexes for metastatic brain disease.
RECURSIVE PARTITIONINGANALYSIS
Class 1 Age<65; KPS≥70, primary controlled; no extra-cranial
disease
Class 2 Patients not in class 1 or 2
Class 3 KPS<70
BASIC SCORE FOR BRAIN METASTASES
Score 0 KPS 50–70; primary uncontrolled; extra-cranial disease
present
Score 1 KPS 80–100; primary controlled; no extra-cranial disease
SCORE INDEX FOR RADIOSURGERY
Score 0 KPS≤50; age≥60; extra-cranial disease progressive;
lesions≥3; volume>13ml (largest lesion)
Score 1 KPS 60–70; age 51–50; extra-cranial disease stable; lesion 2;
volume 5–13ml
Score 2 KPS>80; age≤50; systemic disease NED; lesion 1;
volume<5
GRADED PROGNOSTIC ASSESSMENT
Score 0 KPS<70; age>60; lesions>3; extra-cranial disease
present
Score 0.5 KPS 70–80; age 50–59; lesions 2–3
Score 1 KPS 90–100; age<50; lesion 1; no extra-cranial disease
KPS, Karnofsky performance status; NED, no evidence of disease.
Corticosteroids can be vital drugs in the control of intracranial
edema from BM and the relief of related symptoms. However,
in light of their considerable short- and long-term side effects,
steroids should be used judiciously. Hence, a systematic review on
the subject (16) has made the following recommendations:
• If corticosteroids are given, dexamethasone is the best choice
(level 3).
• Starting doses of 4–8 mg of dexamethasone should be given for
temporary relief of symptoms related to increased intracranial
pressure. In more severe cases,where symptoms suggest impend-
ing herniation, doses of 16 mg/day or more may be considered
(level 3).
• There is insufficient evidence to guide treatment recommenda-
tions for asymptomatic BM.
SURGERY
Up to few decades ago, surgical resection was mainly used to
establish a diagnosis or to alleviate mass-effect symptoms. More
recently, its definitive role in improving disease control for patients
with single, resectable metastasis has been shown to be significant.
Three randomized studies (17–19) have addressed the potential
therapeutic value of surgical resection by comparing surgery fol-
lowed by WBRT vs. WBRT alone in patients with a single brain
metastasis (Table 2).
In two of these trials (17, 18), a survival benefit was reported
for patients undergoing the combined approach. Patchell et al.
(17) randomized 48 good-performing (KPS≥70) patients with an
MRI-diagnosed, tissue-proven single lesion to surgical resection
plus WBRT (36 Gy in 12 fractions) vs. WBRT alone. Of interest,
11% of patients were excluded because no metastatic disease was
seen on the biopsy specimens. The authors reported a statisti-
cally significant improvement in survival (median survival: 40 vs.
15 weeks, p< 0.01) favoring the combined therapy, as well as a
reduction in brain recurrence rates and neurologic death. Vecht at
al. (18) compared WBRT (40 Gy in 20 fractions) with the same
WBRT preceded by surgery. Similarly, the combined approach
showed a survival advantage (median survival: 10 vs. 6 months,
p= 0.04). In this study, patients were stratified for progressive vs.
stable extracranial disease, which proved to be the most important
prognosticator for survival.
In contrast, the study by Mintz et al. (19) failed to show a
survival benefit when WBRT (30 Gy in 10 fractions) followed sur-
gical resection. The median survival for the WBRT group was 6.3
vs. 5.6 months for the combined modality group (p= 0.24). The
median survival in the Mintz et al. (19) series was lower than
the two other randomized studies and may be explained by the
selection of patients with lower KPS or with more extensive extra
cranial systemic disease (45% of patients). In addition, MRI was
not routinely used to exclude multiple metastases.
It should be mentioned that all of these randomized studies had
small patient numbers and did not include relatively radiosensitive
tumors such as small cell lung cancer, lymphoma, myeloma, and
germ cell tumors. Also, these trials were not specific for NSCLC
patients, although this histology was the predominant one in all
trials.
Despite these limitations, the current level 1 evidence sup-
ports the use of WBRT post-surgical resection in patients
with a single, resectable lesion, good performance, and lim-
ited extracranial disease. For patients with multiple metastatic
lesions, poor performance scores, and extensive systemic disease
an evidence-based recommendation for the combined approach
cannot be made.
A follow-up trial by Patchell and colleagues (24) addressed the
real need of WBRT post-resection of a single brain metastasis. In
a multi-center study, 95 patients (60% with NSCLC) with KPS
≥70 undergoing a complete resection of a single brain metasta-
sis were randomized to WBRT (50.4 Gy in 28 fractions) or no
further treatment for a primary end-point of tumor recurrence
anywhere in the brain. A total of 95 patients were randomized and
again NSCLC was the predominant tumor type. The group receiv-
ing post-operative WBRT experienced a significantly lower rate of
brain recurrence (18 vs. 70%, p< 0.001). WBRT also decreased
brain recurrence at the site of the original metastasis (10 vs. 41%,
p< 0.001) and at other sites in the brain (14 vs. 37%, p< 0.01).
Although OS was not different between groups, importantly, post-
operative WBRT significantly prevented death from neurologic
causes (14 vs. 44%, p= 0.003). This trial defined the need for
adjuvant RT post-resection of a single brain metastasis.
RADIATION THERAPY
WHOLE-BRAIN RADIATION THERAPY
The use of WBRT for patients harboring BM is considered by many
as the standard treatment. The rationale for treating the whole
brain is based on the presumption that micro-metastatic deposits
of tumor cells are present elsewhere in the brain. WBRT is the
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Table 2 | Randomized trials ofWBRT in brain metastases.
Author No. patients Randomization Local control Survival (months) pValue
WBRT±SURGERY
Patchell (7) 48 WBRT 48% 3.6 p<0.001
S+WBRT 80% 9.5
Vecht (8) 63 WBRT NR 6.0 p=0.04
S+WBRT 10.0
Mintz (9) 84 WBRT NR 6.3 p=0.39
S+WBRT 5.6
Author No. patients Randomization Local control (%) Survival (months) Neurologic death
WBRT±STEREOTACTIC RADIOSURGERY
Chougule (23) 73 SRS 87 5 NR
SRS+WBRT 91 9
Aoyama (34) 132 SRS 72.5 7.5 19.3%
SRS+WBRT 88.7 8 22.8%
Chang (35) 58 SRS 67 15.2 NR
SRS+WBRT 100 5.7
Kocher (36) 199 SRS 69 10.7 44%
SRS+WBRT 81 10.9 28%
No, number; S, surgery; SRS, stereotactic radiosurgery;WBRT, whole brain radiation therapy; NR, not reported.
most frequently used treatment for the management of BM and
its use is associated with improvement in neurologic symptoms
and decreased neurologic death (25). The RTOG and other inves-
tigators (26–31) conducted several randomized trials evaluating
different dose/fractionation regimens, but no particular regimen
appears to be superior in terms of disease control or survival.
Typically, a dose of 20 Gy in 5 fractions or 30 Gy in 10 fractions
is recommended. Approximately 60% of patients will experience
a complete or partial response with a similar rate for symptoms
improvement, though usually transient.
One major concern with the use of WBRT is the risk of
neurocognitive deficits, particularly short-term memory. Unfor-
tunately, the real rate and magnitude of neurocognitive deficits
post-WBRT has not been properly studied. It has been shown that
over 90% of patients with BM had impairment in one or more
neurocognitive tests at baseline and prior to WBRT (32). Propo-
nents of WBRT argue that it is the disease progression in the brain
not treated by WBRT that, in fact, compromises the patient’s neu-
rocognitive function. However, some patients develop cognitive
problems that cannot be simply explained by disease progression
elsewhere in the brain. Late effects from WBRT are usually seen
after 6 months post-treatment and are secondary to white matter
damage. Considering that many patients will not survive beyond
6 months, it is plausible to consider that cognitive deficits would be
seen in larger proportion of patients should they survive longer.
For a comprehensive review of the subject, we recommend the
paper by McDuff et al. (33).
Recent approaches to reduce the potentially negative effects
of WBRT on cognitive function include the concomitant use of
memantine (20) and hippocampal sparing during WBRT (21).
Memantine, a potential neuroprotector, was used during EBRT in
a recent RTOG randomized trial (20). Patients receiving the drug
had improved cognitive function in several domains. Gondi et al.
(21) presented a phase II RTOG study of hippocampal sparing in
patients undergoing WBRT for BM. Although this was a single
arm trial, the declines in cognitive function are less than what was
observed from historical controls.
STEREOTACTIC RADIOSURGERY
Stereotactic radiosurgery (SRS) delivers a single high dose of
irradiation to the target volume while avoiding the surrounding
normal tissues. A randomized trial conducted by the RTOG (22)
showed that the addition of SRS to WBRT was superior to WBRT
alone in patients with a newly diagnosed single brain lesion. A sur-
vival benefit was not seen for patients with two or three metastatic
lesions, although local brain control was significantly improved
with the addition of SRS. Given its focal delivery of irradiation,
there have been concerns that its isolated use could lead to an
increased rate of failure elsewhere in the brain. However, con-
cerns with cognitive deficits from WBRT led investigators to use
SRS alone in selected patients, reserving WBRT for a later date if
necessary.
To address to this question, four randomized trials have, to
date, compared SRS alone vs. SRS plus WBRT in patients with a
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limited number of metastatic lesions (23, 34–36). One of them has
only been reported in abstract form (23). Table 2 summarizes the
results of these trials.
Despite differences in patient selection and treatment design,
all trials consistently show no significant difference in survival,
but have shown a significant reduction in intracranial failures and
death from brain causes. One study (35) had a neurocognitive end-
point – Hopkins Verbal Learning Test (HVLT) – at 4 months post-
treatment. This small study was stopped prematurely because an
interim analysis showed neurocognitive function at 4 months sig-
nificantly worse after SRS+WBRT than after SRS alone, although
brain control at 1 year was significantly better for the WBRT+ SRS
arm (73 vs. 27%, p= 0.0003). On the other hand, in the Japanese
trial (34), there was a significant decline in mini-mental score when
SRS was given alone making the authors conclude that BM con-
trol was the most important factor for preserving neurocognitive
function.
Whether SRS can replace WBRT in newly diagnosed BM
remains to be determined and treatment decisions should be indi-
vidualized taking into consideration the patients’ wishes, age, intra
and extracranial disease extent, and prognosis.
CHEMOTHERAPY
Due to the failure of most drugs to cross the intact blood–brain
barrier (BBB), the role of chemotherapy in the treatment of BM
has been viewed critically (2). Chemotherapy drugs are generally
large (>150 kDa), ionized, hydrophilic, and often protein-bound,
and therefore, ill-suited to penetrate the tight-junctions, electro-
chemical barrier, astrocyte foot-processes, and highly regulated
transmembrane transport proteins of the central nervous system’s
endothelial vasculature (37).
However, the effects of the BBB may be over-estimated. First,
there is evidence that the BBB of BM is disrupted, as evidenced by
the presence of peritumoral edema and the accumulation of con-
trast media during computed tomography or magnetic resonance
assessments (38, 39). Second, there is evidence of intracranial
tumor response, even to drugs that in healthy systems have lit-
tle central nervous system penetration. In a recent review (37), the
response rates (RRs) of BM to platinum-based regimens in seven
clinical trials of treatment-naïve NSCLC patients were similar to
those achieved extra-cranially, ranging from 30 to 50%. However,
the median survival remained only 5–8 months in most cases. In
the same review, three trials using temozolomide achieved a RR of
only 0–10%, suggesting that the selection of chemotherapy drugs
should be based mainly on their established anti-tumor activity to
extracranial sites, and not on considerations of BBB penetrance.
More recently, two phase II trials have examined the use of cis-
platin and pemetrexed for the treatment of NSCLC with BM. In
one trial, 43 chemo-naive NSCLC patients (93% non-squamous
histology) with BM received up to six cycles of cisplatin and
pemetrexed at standard doses (40). WBRT was given in cases of dis-
ease progression or at chemotherapy completion. Cerebral, extra-
cerebral, and objective RRs by intention to treat (ITT) were 41.9,
34.9, and 34.9%, respectively. Median OS and progression-free
survival (PFS) were 7.4 and 4.0 months, respectively.
In another phase II trial (41), newly diagnosed NSCLC patients
with BM received up to six cycles of cisplatin and pemetrexed
concurrently with WBRT (30 Gy/10 fractions) during days 1–12
of the first cycle. Among the 41 patients evaluable for response
(100% adenocarcinoma), the cerebral, extra-cerebral, and overall
RRs were 68.3, 34.1, and 36.6%, respectively. The median PFS of
BM and OS were 10.6 and 12.6 months, respectively. The hema-
tologic toxicities were generally mild or moderate and there were
no grade 4 or higher non-hematologic toxicities. The combined
treatment was generally safe and well-tolerated.
TARGETED THERAPY
The use of drugs targeting the proteins of mutated EGFR and
anaplastic lymphoma kinase (ALK) genes has become standard of
care in the systemic treatment of metastatic NSCLC (42). In first-
line clinical trials of the EGFR-targeted drugs gefitinib, erlotinib,
and afatinib, objective response rates (ORRs) of 55–83% were
observed, mostly clustering above 70% (43). In addition, large
international phase III trials comparing EGFR tyrosine kinase
inhibitors (TKIs) against platinum doublet chemotherapy have
achieved significant PFS benefits of>4 months with hazard-ratios
(HRs) ranging from 0.37 to 0.58, and improvements to symptoms
and quality of life (44–47).
The ALK-inhibitor crizotinib has also demonstrated strong
anti-tumor activity systemically. In a phase III second-line NSCLC
trial of patients with ALK-rearranged tumors randomized to
receive crizotinib vs. chemotherapy with docetaxel or peme-
trexed, an ORR= 65% was demonstrated, as well as a PFS
benefit of 4.7 months vs. chemotherapy (7.7 vs. 3.0 months,
HR 0.49, p< 0.001) (48). Similarly, in a phase I study of the
newer ALK-inhibitor ceritinib, an ORR= 58% was achieved,
including an ORR= 56% in tumors that had progressed on
crizotinib (49).
The mutation status of tumors is usually derived from biopsies
obtained at extracranial sites, and thus, does not necessarily guar-
antee a mutation in the sub-clones within the brain. However, a
Chinese study of 136 NSCLC patients with resected BM, in which
an EGFR mutation was identified in 57% of the BM, found a con-
cordance rate of 93.3% in the EGFR mutation status between the
primary tumor and BM (50). This suggests that primary tumor
EGFR status is a very good surrogate for EGFR mutation status
of the BM. In this same cohort of patients, the median OS was
24.5 months in the EGFR mutation group, compared to 15 months
in the wild-type group. This finding is consistent with other studies
identifying EGFR mutation status as a positive prognostic factor
among patients with BM (51).
Just as targeted therapy with EGFR and ALK inhibitors is highly
active systemically among molecularly selected NSCLC patients,
there is mounting evidence that this is also true for activity intra-
cranially. A recent review has examined the use of the EGFR
inhibitors gefitinib and erlotinib in BM among NSCLC patients
(6). In the eight phase II clinical trials included in the review, the
intracranial RRs with gefitinib were 27–32% in unselected patients,
43% in an Asian population without molecular selection, and 70–
89% in molecularly selected patients. Similarly, intracranial RRs
were 56 and 82% for erlotinib in clinically and molecularly selected
patients, respectively. Taken together, these results highlight both
robust intracranial activity and the importance of EGFR mutation
status as a predictor of intracranial response. In addition, for the
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three studies where OS data were presented, the median OS results
were 12.9, 18.8, and 19.8 months, respectively.
CONCLUSION
The management of patients with BM has evolved over the
years from an under-studied area to a field of exciting active
research. Supportive therapy, surgery, and RT remain the main-
stays of management for these patients. Additional areas of active
research include techniques to preserve neurocognitive func-
tions with radiotherapy (20, 52), improving the detection and
clinical utility of circulating tumor cells (53), and novel sys-
temic approaches including immunotherapy alone (54, 55) or
in combination with radiotherapy (56), anti-metabolic agents
(57), anti-angiogenesis drugs (58), and novel targeted therapies
for a growing list of oncogenic mutations (59). Ultimately, the
optimal management strategy will employ a multi-disciplinary
approach accounting for individual characteristics of both patient
and tumor.
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